This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsOpsens（OPSS.F）株式概要Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for cardiovascular interventions. 詳細OPSS.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より36.9%で取引されている 収益は年間64.05%増加すると予測されています リスク分析過去1年間で株主の希薄化が進んだ US市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るOPSS.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,132 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,132 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$2.1332.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-12m113m2016201920222025202620282031Revenue CA$112.7mEarnings CA$14.7mAdvancedSet Fair ValueView all narrativesOpsens Inc. 競合他社ElectromedSymbol: NYSEAM:ELMDMarket cap: US$379.4mZynexSymbol: OTCPK:ZYXI.QMarket cap: US$1.7mPulmonxSymbol: NasdaqGS:LUNGMarket cap: US$62.1mSenseonics HoldingsSymbol: NasdaqGS:SENSMarket cap: US$279.3m価格と性能株価の高値、安値、推移の概要Opsens過去の株価現在の株価CA$2.1352週高値CA$2.1452週安値CA$0.97ベータ0.321ヶ月の変化3.01%3ヶ月変化55.12%1年変化54.00%3年間の変化147.17%5年間の変化301.74%IPOからの変化690.33%最新ニュースお知らせ • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.お知らせ • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.お知らせ • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023お知らせ • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.お知らせ • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023お知らせ • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.最新情報をもっと見るRecent updatesお知らせ • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.お知らせ • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.お知らせ • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023お知らせ • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.お知らせ • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023お知らせ • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.株主還元OPSS.FUS Medical EquipmentUS 市場7D0.2%-1.3%0.7%1Y54.0%-18.6%20.6%株主還元を見る業界別リターン: OPSS.F過去 1 年間で-18.6 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: OPSS.F過去 1 年間で20.6 % の収益を上げたUS市場を上回りました。価格変動Is OPSS.F's price volatile compared to industry and market?OPSS.F volatilityOPSS.F Average Weekly Movement15.1%Medical Equipment Industry Average Movement8.5%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%安定した株価: OPSS.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: OPSS.Fの 週次ボラティリティ は、過去 1 年間で10%から15%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003293Louis Laflammeopsens.comもっと見るOpsens Inc. 基礎のまとめOpsens の収益と売上を時価総額と比較するとどうか。OPSS.F 基礎統計学時価総額US$247.03m収益（TTM）-US$9.12m売上高(TTM)US$35.57m6.9xP/Sレシオ-27.1xPER（株価収益率OPSS.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OPSS.F 損益計算書（TTM）収益CA$48.35m売上原価CA$20.37m売上総利益CA$27.97mその他の費用CA$40.38m収益-CA$12.40m直近の収益報告Aug 31, 2023次回決算日該当なし一株当たり利益（EPS）-0.11グロス・マージン57.86%純利益率-25.65%有利子負債／自己資本比率5.4%OPSS.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/13 16:21終値2023/12/12 00:00収益2023/08/31年間収益2023/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Opsens Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関David MartinBloom Burton & Co.Jeffrey CohenLadenburg Thalmann & CompanyCorey HammillParadigm Capital, Inc.3 その他のアナリストを表示
お知らせ • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.
お知らせ • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.
お知らせ • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023
お知らせ • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
お知らせ • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023
お知らせ • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.
お知らせ • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.
お知らせ • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.
お知らせ • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023
お知らせ • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
お知らせ • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023
お知らせ • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.
